Xenon Pharmaceuticals XENE Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's accounts payable and other current liabilities (note 11)?
- Xenon Pharmaceuticals (XENE) reported accounts payable and other current liabilities (note 11) of $38.25M in Q1 2026.
- How has Xenon Pharmaceuticals's accounts payable and other current liabilities (note 11) changed year-over-year?
- Xenon Pharmaceuticals's accounts payable and other current liabilities (note 11) increased by 24.8% year-over-year, from $30.65M to $38.25M.
- What is the long-term trend for Xenon Pharmaceuticals's accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's accounts payable and other current liabilities (note 11) has grown at a 29.9% compound annual growth rate (CAGR), from $10.87M to $40.26M.